(Sharecast News) - ValiRx announced a new wholly owned subsidiary Blue Ribbon Bio on Tuesday, to consolidate its prostate cancer assets and accelerate development of its Val201 peptide therapy.
The AIM-traded life sciences company said Blue Ribbon would initially hold intellectual property for Val201, licensed from Cancer Research Horizons in 2010,...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE